“the long term benefit of integrating the Polish unit under BioPharmcor BV will yield substantial performance efficiencies and ancillary stakeholder gains in the future.
Ottawa, Canada (PRWEB) June 29, 2015
In a move that will set the corporate structure of early stage generic drug producer BioPharmcor, Ottawa based VMS Rehab Systems Inc, (http://www.vmsrehabsystemsinc.com) reports that it has completed the restructure of its holdings in Poland based BioPharmcor Sp Z o.o.(http://www.biopharmcor.pl) under BioPharmcor BV, a recently formed Netherlands company.
A spokesperson for VMS explains that “the long term benefit of integrating the Polish unit under BioPharmcor BV will yield substantial performance efficiencies and ancillary stakeholder gains in the future. Moreover, with a base of operations in both Central and Western Europe, BioPharmcor’s market reach throughout the European Community, will be significantly upgraded by this move.”
Amsterdam based BioPharmcor BV, in conjunction with its newly acquired Warsaw based subsidiary, BioPharmcor Sp z o.o.. are currently formulating and developing a line of generic pharmaceuticals keyed to advancing Men’s Health. BioPharmcor plans to introduce into the marketplace by late 2016, safe and affordable generic drugs to treat Erectile Dysfunction (ED) and Benign Prostatic Hyperplasia (BPH), two common disorders in men over the age of 40.
VMS Rehab Systems, Inc, is headquartered in Ottawa, Canada. In addition to its activities in the generic drugs business for advancing Men’s health, the Company distributes home health products throughout Canada (http://www.vmsrehabsystems.ca) . Shares of VMS Rehab Systems, Inc are listed on the US OTC Pink Current Market (Symbol: VRSYF).
Certain statements contained in this press release constitute forward-looking information. These statements relate to future events or future performance. The use of any of the words "will" and similar expressions and statements relating to matters that are not historical facts are intended to identify forward-looking information and are based on the Corporation's current belief or assumptions as to the outcome and timing of such future events. Actual future results may differ materially. Various assumptions or factors are typically applied in drawing conclusions or making the forecasts or projections set out in forward-looking information. Those assumptions and factors are based on information currently available to the Corporation. The forward-looking information contained in this release is made as of the date hereof and the Corporation is not obligated to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable securities laws. Because of the risks, uncertainties and assumptions contained herein, investors should not place undue reliance on forward-looking information. The foregoing statements expressly qualify any forward-looking information contained herein.